Elite Pharmaceuticals, Inc.
ELTP · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.90 | -0.08 | 0.00 | 0.06 |
| FCF Yield | 1.06% | -2.63% | -8.16% | 17.01% |
| EV / EBITDA | 163.34 | 63.41 | 3.96 | 4.55 |
| Quality | ||||
| ROIC | 1,809.64% | 619.48% | 6,710.61% | 21.72% |
| Gross Margin | 47.70% | 46.55% | 48.58% | 45.86% |
| Cash Conversion Ratio | -1.73 | -0.16 | 0.94 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -86.50% | 20.63% | 1,004.04% | 21.48% |
| Free Cash Flow Growth | 220.52% | -70.62% | -139.90% | 109.85% |
| Safety | ||||
| Net Debt / EBITDA | -0.14 | 1.84 | -0.61 | -0.89 |
| Interest Coverage | 25.38 | 18.33 | 1,819.99 | 26.44 |
| Efficiency | ||||
| Inventory Turnover | 2.71 | 2.34 | 1,838.72 | 2.59 |
| Cash Conversion Cycle | 237.14 | 248.59 | 0.18 | 145.56 |